{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:58:06Z","timestamp":1784872686282,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62372143"],"award-info":[{"award-number":["62372143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["LH2019C042"],"award-info":[{"award-number":["LH2019C042"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-025-01584-9","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:26:29Z","timestamp":1764645989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PathHDNN: a pathway hierarchical-informed deep neural network framework for predicting immunotherapy response and mechanism interpretation"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiangmei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"4","key":"1584_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"6","key":"1584_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","volume":"27","author":"D Liu","year":"2021","unstructured":"Liu D, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021;27(6):985\u201392.","journal-title":"Nat Med"},{"issue":"5","key":"1584_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cell.2024.01.027","volume":"187","author":"F Petralia","year":"2024","unstructured":"Petralia F, et al. Pan-cancer proteogenomics characterization of tumor immunity. Cell. 2024;187(5):1255\u2013e127727.","journal-title":"Cell"},{"issue":"26","key":"1584_CR4","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"1584_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"17","key":"1584_CR6","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational Burden-High solid tumors. Clin Cancer Res. 2021;27(17):4685\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1584_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, et al. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1584_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929\u201338.","journal-title":"Ann Oncol"},{"issue":"26","key":"1584_CR9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"15","key":"1584_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"1584_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, et al. High tumor mutation burden fails to predict immune checkpoint Blockade response across all cancer types. Ann Oncol. 2021;32(5):661\u201372.","journal-title":"Ann Oncol"},{"key":"1584_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","volume":"8","author":"R Bai","year":"2020","unstructured":"Bai R, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8:34.","journal-title":"Biomark Res"},{"issue":"1","key":"1584_CR13","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","volume":"13","author":"J Kong","year":"2022","unstructured":"Kong J, et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun. 2022;13(1):3703.","journal-title":"Nat Commun"},{"issue":"4","key":"1584_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell D, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2022;40(4):499\u2013506.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1584_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4627","volume":"15","author":"J Ma","year":"2018","unstructured":"Ma J, et al. Using deep learning to model the hierarchical structure and function of a cell. Nat Methods. 2018;15(4):290\u20138.","journal-title":"Nat Methods"},{"issue":"5","key":"1584_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","volume":"38","author":"BM Kuenzi","year":"2020","unstructured":"Kuenzi BM, et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell. 2020;38(5):672\u2013e6846.","journal-title":"Cancer Cell"},{"key":"1584_CR17","doi-asserted-by":"crossref","unstructured":"Jiang Y et al. IRnet: immunotherapy response prediction using pathway knowledge-informed graph neural network. J Adv Res. 2024;72:319\u201331.","DOI":"10.1016\/j.jare.2024.07.036"},{"issue":"5","key":"1584_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"12","key":"1584_CR19","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"issue":"1","key":"1584_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"6257","key":"1584_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311.","journal-title":"Science"},{"issue":"23","key":"1584_CR22","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"1584_CR23","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"D1","key":"1584_CR24","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"7880","key":"1584_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","volume":"598","author":"HA Elmarakeby","year":"2021","unstructured":"Elmarakeby HA, et al. Biologically informed deep neural network for prostate cancer discovery. Nature. 2021;598(7880):348\u201352.","journal-title":"Nature"},{"issue":"2","key":"1584_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22(2):127\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"1584_CR27","doi-asserted-by":"crossref","unstructured":"Hsiue EH et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371(6533):eabc8697.","DOI":"10.1126\/science.abc8697"},{"issue":"W1","key":"1584_CR28","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1584_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1074-7613(03)00332-7","volume":"19","author":"Y Laouar","year":"2003","unstructured":"Laouar Y, et al. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19(6):903\u201312.","journal-title":"Immunity"},{"issue":"1","key":"1584_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ng0501-29","volume":"28","author":"H Yoshikawa","year":"2001","unstructured":"Yoshikawa H, et al. SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28(1):29\u201335.","journal-title":"Nat Genet"},{"issue":"3","key":"1584_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1584_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ccell.2022.12.009","volume":"41","author":"MA Coelho","year":"2023","unstructured":"Coelho MA, et al. Base editing screens map mutations affecting interferon-gamma signaling in cancer. Cancer Cell. 2023;41(2):288\u2013e3036.","journal-title":"Cancer Cell"},{"issue":"1","key":"1584_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7(1):331.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1584_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf P, et al. Acidosis-mediated increase in IFN-gamma-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer. 2023;22(1):207.","journal-title":"Mol Cancer"},{"issue":"4","key":"1584_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo L, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint Blockade. Immunity. 2022;55(4):671\u2013e68510.","journal-title":"Immunity"},{"issue":"5","key":"1584_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, et al. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1584_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1584_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159.","journal-title":"Mol Cancer"},{"issue":"7","key":"1584_CR39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, et al. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964\u201375.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1584_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, et al. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635\u201347.","journal-title":"Nat Rev Immunol"},{"issue":"47","key":"1584_CR41","doi-asserted-by":"publisher","first-page":"e2004853","DOI":"10.1002\/adma.202004853","volume":"32","author":"L Rao","year":"2020","unstructured":"Rao L, et al. Activating Macrophage-Mediated cancer immunotherapy by genetically edited nanoparticles. Adv Mater. 2020;32(47):e2004853.","journal-title":"Adv Mater"},{"issue":"10","key":"1584_CR42","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"1584_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"22","key":"1584_CR44","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","volume":"78","author":"Z Wang","year":"2018","unstructured":"Wang Z, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint Blockade. Cancer Res. 2018;78(22):6486\u201396.","journal-title":"Cancer Res"},{"issue":"1","key":"1584_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13073-022-01024-y","volume":"14","author":"J Long","year":"2022","unstructured":"Long J, et al. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Med. 2022;14(1):20.","journal-title":"Genome Med"},{"issue":"9","key":"1584_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41389-019-0157-8","volume":"8","author":"F Gao","year":"2019","unstructured":"Gao F, et al. DeepCC: a novel deep learning-based framework for cancer molecular subtype classification. Oncogenesis. 2019;8(9):44.","journal-title":"Oncogenesis"},{"issue":"6","key":"1584_CR47","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.crmeth.2024.100797","volume":"4","author":"J Xie","year":"2024","unstructured":"Xie J, et al. Tracing unknown tumor origins with a biological-pathway-based transformer model. Cell Rep Methods. 2024;4(6):100797.","journal-title":"Cell Rep Methods"},{"key":"1584_CR48","doi-asserted-by":"crossref","unstructured":"Wang H et al. HyperTMO: a trusted multi-omics integration framework based on hypergraph convolutional network for patient classification. Bioinformatics. 2024;40(4):btae159.","DOI":"10.1093\/bioinformatics\/btae159"},{"key":"1584_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jare.2024.07.036","volume":"72","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, et al. IRnet: immunotherapy response prediction using pathway knowledge-informed graph neural network. J Adv Res. 2025;72:319\u201331.","journal-title":"J Adv Res"},{"key":"1584_CR50","doi-asserted-by":"crossref","unstructured":"Tanvir RB et al. MOGAT: A Multi-Omics integration framework using graph attention networks for cancer subtype prediction. Int J Mol Sci. 2024;25(5):2788.","DOI":"10.3390\/ijms25052788"},{"key":"1584_CR51","doi-asserted-by":"crossref","unstructured":"Ryan B, Marioni RE, Simpson TI. Multi-Omic graph diagnosis (MOGDx): a data integration tool to perform classification tasks for heterogeneous diseases. Bioinformatics. 2024;40(9):btae523.","DOI":"10.1093\/bioinformatics\/btae523"},{"issue":"1","key":"1584_CR52","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1038\/s41467-021-23774-w","volume":"12","author":"T Wang","year":"2021","unstructured":"Wang T, et al. MOGONET integrates multi-omics data using graph convolutional networks allowing patient classification and biomarker identification. Nat Commun. 2021;12(1):3445.","journal-title":"Nat Commun"},{"issue":"3","key":"1584_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-23-0641","volume":"14","author":"X Zhao","year":"2024","unstructured":"Zhao X, et al. Cancer mutations converge on a collection of protein assemblies to predict resistance to replication stress. Cancer Discov. 2024;14(3):508\u201323.","journal-title":"Cancer Discov"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01584-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:02:11Z","timestamp":1766574131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-025-01584-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01584-9","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized exclusively pre-existing, de-identified data from the cBioPortal for Cancer Genomics (\n                      \n                      ). All data were accessed and analyzed in accordance with the cBioPortal\u2019s terms of use. In compliance with the official policy of the Harbin Medical University Institutional Review Board (IRB)\/Ethics Committee, this research, which involves the secondary analysis of such publicly available, non-identifiable data, is not classified as human subjects research and therefore did not require separate ethical approval from the committee. The original primary studies that contributed data to cBioPortal were conducted in accordance with the ethical standards of the World Medical Association\u2019s Declaration of Helsinki, including the procurement of informed consent from their respective participants. Our secondary analysis adhered to the ethical principles governing the use of such data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}